[Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino acids in a somatostatin or an analog thereof being replaced by glycosylated amino acids.

A problem is to provide a prebiotic which promotes the growth of a butyrate-producing bacterium. A prebiotic composition is described that promotes the growth of a butyrate-producing bacterium which contains alginic acid and/or a salt thereof.

The invention relates to methods and compositions for the production of fucosylated oligosaccharides.

The present invention relates to a composition for use in an orally, or rectally, transdermally or nasally administered medicament, characterized in that it includes: (b) at least one compound of Formula (I) and (b) at least one permeation enhancer, selected from the group consisting of saturated and/or unsaturated organic fatty acids, or pharmaceutically and pharmacologically acceptable salts thereof, and thiomers. It further relates to a pharmaceutical formulation comprising said composition. It furthermore relates to bioreversible esters of compounds of Formula (I).

##STR00001##

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

An ingestible composition including a probiotic contained in a mixture of hydrolyzed mammalian protein, one or more carbohydrates and a compound binder useful for nutrition of infants and children.

There are provided novel synthetic stool preparations comprising bacteria isolated from a fecal sample from a healthy donor. The synthetic stool preparations are used for treating disorders of the gastrointestinal tract, including dysbiosis, Clostridium difficile infection and recurrent Clostridium difficile infection, prevention of recurrence of Clostridium difficile infection, treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, and diverticular disease, and treatment of food poisoning such as salmonella. Methods of preparation and methods of use of the synthetic stool preparations are also provided.

The present invention pertains to a vaccine for use in protecting offspring of a sow against an infection with porcine endemic diarrhea virus (PEDV), the vaccine comprising non-live PEDV antigen and an oil containing adjuvant, by administration of the vaccine to the pregnant sow at a dose of the antigen corresponding to at least 3.0E6 TCID50 killed whole PEDV. The invention also pertains to a method of protecting young piglets against an infection with porcine endemic diarrhea virus (PEDV).

The present invention relates to a composition for ameliorating viral infections in nursery pigs. The composition contains the polyether ionophore narasin, and is supplied to the nursery pigs in an orally-acceptable form. The composition is effective in reducing viral shedding and the severity of diarrhea after challenge of nursery pigs with Porcine Epidemic Diarrhea Virus (PEDV).

Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.